Featured Research

from universities, journals, and other organizations

New Oral Medication Halts Blindness In AIDS Patients

Date:
April 25, 2002
Source:
University Of Toronto
Summary:
A viral infection that robs AIDS patients of their sight can now be fought with a drug in pill form, allowing patients a better quality of life, say the authors of a recent paper in The New England Journal of Medicine.

A viral infection that robs AIDS patients of their sight can now be fought with a drug in pill form, allowing patients a better quality of life, say the authors of a recent paper in The New England Journal of Medicine.

Related Articles


Prior to this research, physicians treated the infection cytomegalovirus (CMV) retinitis with a drug called ganciclovir, which was only available intravenously. "Patients had permanent catheters - akin to intravenous lines - inserted into the large veins in the chest," says Dr. Sharon Walmsley of the University of Toronto's medicine department and a senior scientist at the University Health Network (Toronto General Hospital). "They had to self-administer the drug (or with the help of a nurse or other person) once or twice a day for the rest of their lives. It was very inconvenient, made working or travel difficult and patients were prone to infections of the lines resulting in blood infection. Also, patient privacy was compromised as anyone who saw the line immediately knew they were ill."

In clinical trials with 160 AIDS patients, the international team of researchers found the pills, called valganciclovir, to be as effective as the traditional intravenous treatment.

CMV retinitis is the leading cause of blindness among patients in the late stages of AIDS. While the infection originates from a germ or virus to which most people have been exposed, it lies dormant in the general population. However, if a person's immune system is damaged - as in the case of HIV or transplant patients - the virus can reactivate. The incidence of blindness caused by CMV retinitis has dropped considerably, largely due to better HIV treatments. Other investigators are now examining whether the pills are as effective in transplant patients. The research was funded by Roche Pharmaceuticals.


Story Source:

The above story is based on materials provided by University Of Toronto. Note: Materials may be edited for content and length.


Cite This Page:

University Of Toronto. "New Oral Medication Halts Blindness In AIDS Patients." ScienceDaily. ScienceDaily, 25 April 2002. <www.sciencedaily.com/releases/2002/04/020425072505.htm>.
University Of Toronto. (2002, April 25). New Oral Medication Halts Blindness In AIDS Patients. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2002/04/020425072505.htm
University Of Toronto. "New Oral Medication Halts Blindness In AIDS Patients." ScienceDaily. www.sciencedaily.com/releases/2002/04/020425072505.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins